TacticScaleWhat LivaNova Does & How It Makes Money (LIVN)
Updated October 2026 · reflects LivaNova's latest reported financials
Medical device maker of heart-lung and nerve-stimulation therapy systems. It earns revenue by selling cardiopulmonary equipment, disposables such as oxygenators, tubing and cannulas, and related services, plus implantable VNS Therapy systems, to hospitals and medical institutions.
How LivaNova makes money
It earns revenue by selling cardiopulmonary equipment, disposables such as oxygenators, tubing and cannulas, and related services, plus implantable VNS Therapy systems, to hospitals and medical institutions. Sales go through direct reps, agents and independent distributors in the US, Europe and other markets.
What LivaNova does
LivaNova PLC is a UK-headquartered medical technology company, incorporated in 2015, with two segments. The Cardiopulmonary segment supplies the equipment perfusionists use in heart surgery: heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing, cannulas and accessories, plus related services. The Neuromodulation segment is built around the VNS Therapy System, an implanted pulse generator and lead that stimulates the vagus nerve to treat drug-resistant epilepsy and depression. The segment is also developing and clinically testing the aura6000 system for obstructive sleep apnea. LivaNova sells to hospitals, neurologists, neurosurgeons and other providers through direct sales, agents and distributors across the US, Europe and other markets.
Products & services
- VNS Therapy System
- Heart-lung machines
- Oxygenators
- Autotransfusion systems
- Perfusion tubing systems and cannulas
- aura6000 system (in development)
What is LivaNova worth?
On an owner-earnings DCF, LivaNova's most-likely value is about $84 versus a recent price near $76 (10% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$33) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Medtronic (MDT) · Intuitive Surgical (ISRG) · Edwards Lifesciences (EW) · Artivion (AORT) · LeMaitre Vascular (LMAT)